TEL AVIV, Israel, May 3, 2017 /PRNewswire/ -- Therapix Biosciences
Ltd. (Nasdaq: TRPX) ("Therapix"), a specialty clinical stage
pharmaceutical company specializing in the development of
cannabinoid-based drugs, today announced that it has appointed
Josh Blacher as Chief Financial
Officer, effective immediately.
Mr. Blacher joins Therapix with ten years of experience in
senior financial and business development related positions at
publicly-traded biotechnology and pharmaceutical companies, as well
as 14 years in capital markets in the United States. Prior to
joining Therapix, Mr. Blacher served as Chief Financial Officer at
Galmed Pharmaceuticals (NASDAQ: GLMD). Previously, Mr.
Blacher also held senior positions in licensing and investing at
Teva Pharmaceuticals, portfolio management at Deutsche Asset
Management and equity research at Morgan Stanley, as well as in
mergers & acquisitions at Lehman Brothers. Mr. Blacher
holds an MBA in Finance from Columbia Business
School.
"Now that Therapix has completed its U.S. IPO and NASDAQ
listing, and initiated additional clinical trials, it is clear that
we will need someone of Josh's caliber to help us develop and bring
awareness of our growth strategy to the U.S. capital markets, as
well as monetize our assets globally. We're confident that
Josh's broad-based experience and track record will help us
accomplish our objectives," commented Dr. Elran Haber, Therapix's
Chief Executive Officer and Dr. Ascher
Shmulewitz, the Company's Executive Chairman. Drs.
Haber and Shmulewitz continued, "We're delighted to welcome Josh to
the company."
"Therapix has all the makings of a successful specialty
pharmaceutical company – compelling technology in areas of high
unmet medical needs, strong management and long-term investors, as
well as the financial wherewithal to execute its strategy,"
commented Mr. Blacher. "I am very excited to join Therapix
and look forward to helping the company unlock its significant
potential."
About Therapix Biosciences
Therapix Biosciences Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior
executives and scientists, focused on creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the company is currently engaged
in two internal drug development programs based on repurposing an
FDA approved synthetic cannabinoid (dronabinol): Joint Pharma,
developing THX-TS01 targeted to the treatment of Tourette's
syndrome; and BrainBright Pharma, developing THX-ULD01 targeted to
the high value and under-served market of mild cognitive
impairments. More information is available online at
http://www.therapixbio.com.
Forward-Looking Statements
This press release contains forward-looking statements about the
Company's expectations, beliefs, and intentions. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe", "expect", "intend", "plan", "may", "should",
"could", "might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. For
example, forward-looking statements are used in this press release
when we discuss accomplishing our objectives and that we have the
financial wherewithal to execute our strategy. These
forward-looking statements involve certain risks and uncertainties,
including, among others, risks that could cause the Company's
results to differ materially from those expected by Company
management or otherwise described in or implied by the statements
in this press release. Any forward-looking statement in this press
release speaks only as of the date of this press release. The
Company undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws. More detailed information about the
risks and uncertainties affecting the Company is contained under
the heading "Risk Factors" in Therapix Biosciences Ltd.'s annual
report on Form 20-F dated May 1, 2017
filed with the SEC, which is available on the SEC's website,
http://www.sec.gov.
For further information: Investor Contact:
Josh Blacher, CFO
Therapix Biosciences
josh@therapixbio.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/therapix-biosciences-announces-the-appointment-of-josh-blacher-as-chief-financial-officer-300450536.html
SOURCE Therapix Biosciences Ltd